Contrasting Senti Biosciences (NASDAQ:SNTI) and Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Voyager Therapeutics and Senti Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	N/A	69.09%	38.58%
Senti Biosciences	-1,785.30%	-60.56%	-42.81%

Earnings & Valuation

This table compares Voyager Therapeutics and Senti Biosciences’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$194.87 million	1.81	-$46.41 million	$2.27	3.54
Senti Biosciences	$4.29 million	5.48	-$58.21 million	($1.64)	-0.32

Voyager Therapeutics has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Voyager Therapeutics and Senti Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	0	0	2	0	3.00
Senti Biosciences	0	2	2	0	2.50

Voyager Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 109.88%. Senti Biosciences has a consensus price target of $4.00, indicating a potential upside of 665.55%. Given Senti Biosciences’ higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Voyager Therapeutics.

Volatility & Risk

Voyager Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.

Institutional and Insider Ownership

58.8% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 27.4% of Senti Biosciences shares are owned by institutional investors. 4.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Voyager Therapeutics beats Senti Biosciences on 9 of the 13 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.